# HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes

> **NCT06550063** · — · RECRUITING · sponsor: **St. James's Hospital, Ireland** · enrollment: 2188 (estimated)

## Conditions studied

- Esophagus Cancer
- Gastric Cancer
- HER2-positive Cancer
- HER2-low Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06550063
- **Lead sponsor:** St. James's Hospital, Ireland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-20
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 2188 (ESTIMATED)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06550063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06550063, "HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06550063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*